Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2006

View Archived Issues

Levetiracetam effective in human experimental pain

Increased heparanase expression correlated with invasive breast cancer

Progress update on ThromboView programs

Antisoma to evaluate EcoBiotics' rainforest anticancer compounds

CeNeS collaborates with Ergomed to finalize phase II trial plans for CNS-5161

New phase I/II trial evaluates BDM-E for diabetic macula edema

Phase III trials completed for KW-6002 in Parkinson's disease

Biotest and AERES Biomedical establish production system for BT-062

OP-145 for chronic otitis media completes phase I, begins phase II

CancerVax files to begin phase I trial with D93

Immtech completes SPA for DB-289 in Pneumocystis pneumonia

Ciclesonide nasal spray NDA accepted for review

Pivotal study begins for KeraPac in diabetic foot ulcers

GSK and Myogen form PAH partnership

Phase II pagoclone study in stuttering completes enrollment

Enrollment completed in first of two phase III studies for Sanctura XR

Neuren cleared to advance NNZ-2566 into phase I for traumatic brain injury

ATL-104 reduces duration of mucositis

Ceftobiprole demonstrates high cure rate in Gram-positive infections

Therapeutic agents for HIV infection claimed in recent patent literature

FDA Advisory Committee recommends return of Tysabri to market

Novel PKC-theta inhibitors emerge from Boehringer Ingelheim R&D

Recent patents report new possible treatments for respiratory diseases

RB-101: antidepressant without associated convulsions

The beneficial effects of argan oil phenolic extract for CHD

Safety of docetaxel in combination with immunotherapy shown in patients with prostate cancer

Efficacy of theophylline to treat allergic asthma improved by new delivery system

Potential application of Neovastat in inflammatory asthma reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...